Efficacy of IL-17 blockers on the combined course of advanced psoriasis vulgaris and chronic gastritis: a case report
Russian Journal of Skin and Venereal Diseases · 22.09.2026 · 29 (5) · 625-634
DOI: 10.17816/dv717039 ↗Kurz gefasst
Fallbericht in der Zeitschrift Russian Journal of Skin and Venereal Diseases, online erschienen am 22.09.2026. Verfasst von Antonina A. Arsenyeva und 4 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Increased expression of interleukin-17A (IL-17A) has been demonstrated in gastric mucosal biopsy specimens and lamina propria lymphocyte cultures of patients with Helicobacter pylori-associated gastritis. IL-17A is considered one of the central mediators of the neutrophilic inflammatory response in H. pylori infection. Experimental studies have shown that inactivation of the IL17A gene or its receptor leads to reduced neutrophilic infiltration of the gastric mucosa, indicating a key role of this cytokine in the initiation and maintenance of local inflammation. In addition to promoting IL-8 production, IL-17A enhances the synthesis of other pro-inflammatory cytokines and chemokines, thereby contributing to chronic inflammation and gastric tissue damage. In children with concurrent psoriasis and H. pylori-associated gastritis, elevated IL-17A levels may exacerbate both conditions. This report presents the results of an interdisciplinary clinical observation of a patient with psoriasis and concomitant gastrointestinal pathology, with a focus on the efficacy and safety of biologic therapy. We report the clinical management of a 16-year-old female patient with extensive progressive psoriasis. Her comorbid condition was chronic H. pylori-associated gastritis in the subacute phase. Following a multidisciplinary consultation involving both a dermatologist and a gastroenterologist, treatment with secukinumab, an IL-17 inhibitor, was initiated. Treatment efficacy was assessed 1.5 months after the initiation of biologic therapy. A marked improvement in skin lesions was observed, with psoriasis entering a stage of clinical regression. Simultaneously, symptoms of chronic gastritis resolved. No gastrointestinal adverse events were reported. H. pylori eradication therapy, conducted during biologic therapy, contributed to the reduction of active gastric mucosal inflammation and to a lower long-term risk of atrophic gastritis and gastric carcinogenesis. At present, secukinumab is being continued at a dose of 300 mg administered subcutaneously as maintenance biologic anti-inflammatory therapy. A multidisciplinary approach to the management of patients with psoriasis allows for the timely identification of comorbidities and the prescription of necessary medication correction, thereby improving patient adherence to long-term treatment and increasing the chances of sustained remission.
Zitieren
APA
Arsenyeva, A. A., Orlov, E. V., Khlopova, E. S., Trifonova, E. A., & Nesterova, E. I. (2026). Efficacy of IL-17 blockers on the combined course of advanced psoriasis vulgaris and chronic gastritis: a case report. Russian Journal of Skin and Venereal Diseases, 29(5), 625-634. https://doi.org/10.17816/dv717039
Vancouver
Arsenyeva AA, Orlov EV, Khlopova ES, Trifonova EA, Nesterova EI. Efficacy of IL-17 blockers on the combined course of advanced psoriasis vulgaris and chronic gastritis: a case report. Russian Journal of Skin and Venereal Diseases. 2026;29(5):625-634. doi:10.17816/dv717039
BibTeX
@article{Arsenyeva2026,
author = {Arsenyeva, Antonina A. and Orlov, Evgeniy V. and Khlopova, Elvira Sh. and Trifonova, Elena A. and Nesterova, Ekaterina I.},
title = {Efficacy of IL-17 blockers on the combined course of advanced psoriasis vulgaris and chronic gastritis: a case report},
journal = {Russian Journal of Skin and Venereal Diseases},
year = {2026},
volume = {29},
number = {5},
pages = {625--634},
doi = {10.17816/dv717039}
}
EUVIMED